TOPOTECAN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Topotecan Hydrochloride, and what generic alternatives are available?
Topotecan Hydrochloride is a drug marketed by Accord Hlthcare, Actavis Totowa, Dr Reddys Labs Ltd, Fresenius Kabi Usa, Meitheal, Novast Labs, Rising, Sagent Pharms, Sun Pharm Inds Ltd, Teyro Labs, Dash Pharms, and Hospira Inc. and is included in fifteen NDAs.
The generic ingredient in TOPOTECAN HYDROCHLORIDE is topotecan hydrochloride. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Topotecan Hydrochloride
A generic version of TOPOTECAN HYDROCHLORIDE was approved as topotecan hydrochloride by FRESENIUS KABI USA on November 29th, 2010.
Summary for TOPOTECAN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 108 |
Clinical Trials: | 434 |
Patent Applications: | 7,181 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TOPOTECAN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TOPOTECAN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Amgen | Phase 3 |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
Bristol-Myers Squibb | Phase 2 |
Pharmacology for TOPOTECAN HYDROCHLORIDE
Drug Class | Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |